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Synthesis of N-Glycolylneuraminic
Acid (Neu5Gc) and Its Glycosides
Anoopjit Singh Kooner, Hai Yu and Xi Chen*
Department of Chemistry, University of California, Davis, Davis, CA, United States
Sialic acids constitute a family of negatively charged structurally diverse
monosaccharides that are commonly presented on the termini of glycans in higher
animals and some microorganisms. In addition to N-acetylneuraminic acid (Neu5Ac),
N-glycolyl neuraminic acid (Neu5Gc) is among the most common sialic acid forms in
nature. Nevertheless, unlike most animals, human cells loss the ability to synthesize
Neu5Gc although Neu5Gc-containing glycoconjugates have been found on human
cancer cells and in various human tissues due to dietary incorporation of Neu5Gc. Some
pathogenic bacteria also produce Neu5Ac and the corresponding glycoconjugates
but Neu5Gc-producing bacteria have yet to be found. In addition to Neu5Gc, more
than 20 Neu5Gc derivatives have been found in non-human vertebrates. To explore
the biological roles of Neu5Gc and its naturally occurring derivatives as well as the
corresponding glycans and glycoconjugates, various chemical and enzymatic synthetic
methods have been developed to obtain a vast array of glycosides containing Neu5Gc
and/or its derivatives. Here we provide an overview on various synthetic methods
that have been developed. Among these, the application of highly efficient one-pot
multienzyme (OPME) sialylation systems in synthesizing compounds containing Neu5Gc
and derivatives has been proven as a powerful strategy.
Keywords: sialic acid, sialoside, Neu5Gc, chemical synthesis, chemoenzymatic synthesis
INTRODUCTION
Sialic acids (Sias) are a family of negatively charged monosaccharides with a nine carbon
backbone. More than 50 structurally distinct Sias have been found in nature (1–3), out of
which more than 15 have been identified in human (4–6). They are commonly presented as
the terminal monosaccharides of the carbohydrate moieties of glycoproteins and glycolipids on
cell surface of deuterostome animals, in secreted glycans and glycoconjugates including those
in the milk of mammals (2, 7–9). Some microorganisms including pathogenic bacteria also
produce sialic acid and sialic acid-containing structures (7, 10). Three basic forms of sialic
acids are N-acetylneuraminic acid (Neu5Ac), N-glycolylneuraminic acid (Neu5Gc), and 2-keto-3-
deoxynonulosonic acid (Kdn) (Figure 1A) (1–3). In nature, sialic acid-containing oligosaccharides
and glycoconjugates are formed mainly by sialyltransferase-catalyzed reactions transferring sialic
acid from its activated sugar nucleotide, cytidine 5′-monophosphate-sialic acid (CMP-Sia), to
suitable acceptors (11) although trans-sialidases have also been used by parasites and bacteria to
harvest sialic acids from the hosts to decorate their own surface (12, 13). Neu5Ac is the most
common form of sialic acids. Compared to Neu5Ac, Neu5Gc has an extra oxygen, presented as
the hydroxyl in the N-glycolyl group at C-5.
Kooner et al. Neu5Gc and Glycoside Synthesis
GRAPHICAL ABSTRACT | Chemical and chemoenzymatic synthetic methods for Neu5Gc and Neu5Gc-sialosides are reviewed. One-pot multienzyme (OPME)
chemoenzymatic strategy has advantages in accessing a large number of Neu5Gc-sialosides and their derivatives.
The biosynthesis of Neu5Ac from uridine 5′-diphosphate
N-acetylglucosamine (UDP-GlcNAc) in eukaryotic cells takes
place in the cytosol by three enzymes. The first two committed
steps are hydrolytic epimerization of UDP-GlcNAc to form
N-acetylmannosamine (ManNAc) followed by phosphorylation
to form ManNAc-6-P catalyzed by a single bifunctional
enzyme UDP-GlcNAc 2-epimerase/ManNAc-6-kinase (GNE).
Phosphoenolpyruvate is then condensed with ManNAc-6-P by
Neu5Ac 9-phosphate synthase (NAPS) to produce Neu5Ac-9-
P which is dephosphorylated to form Neu5Ac by Neu5Ac-9-
phosphate phosphatase (NANP). The Neu5Ac synthesized in
the cytosol is transferred into nucleus and used to form CMP-
Neu5Ac, the activated form of Neu5Ac, by CMP-sialic acid
synthetase (CSS). CMP-Neu5Gc formed in the cytosol from
CMP-Neu5Ac by CMP-Neu5Ac hydroxylase (CMAH)-catalyzed
reaction (11, 14–17) is transferred into Golgi and used by
various sialyltransferases to form glycoconjugates which are
secreted or expressed on cell surfaces (Figure 1B) (10, 18, 19).
The CMAH gene is inactive in humans. Therefore, humans
do not biosynthesize Neu5Gc-containing structures themselves
(20, 21). New World monkeys were also shown to loss the
function of Neu5Gc production due to an independent CMAH
inactivation (22).
Regardless of CMAH inactivation in human, Neu5Gc has
been found on the cell surface of human tumors and even
in normal human tissues although at a lower amount (23,
24). Neu5Gc in human glycoconjugates comes likely from the
consumption of animal-derived diets, such as red meat and
animal milk (25–27). On the other hand, during infancy (around
the age of 6 months) humans develop varying levels of polyclonal
antibodies of IgG (28, 29), IgM, and IgA (30, 31) types against
a diverse array of Neu5Gc-containing glycans (32–35). The
mechanism of developing such anti-Neu5Gc antibodies early
in the human life is unclear although incorporating dietary
Neu5Gc by bacteria colonized in humans, such as non-typeable
Haemophilus influenzae (NTHi) to form Neu5Gc-containing
epitopes, such as cell surface lipooligosaccharides (LOS) is a likely
source of the corresponding immunogens (32, 36, 37). So far,
de novo synthesis of Neu5Gc and Neu5Gc-containing structures
has not been demonstrated in bacteria. The presence of CMAH-
like sequences has been found in the genomes of some bacteria
but the activities of the corresponding enzymes have not been
confirmed (38–40).
The presence of Neu5Gc-containing xeno-auto-antigens and
anti-Neu5Gc xeno-autoantibodies in human (24) may lead to
potential complications, such as chronic inflammation namely
“xenosialitis” (41), atherosclerotic cardiovascular diseases,
cancers, and autoimmune diseases (34, 38, 42–45). In addition,
exposure to clinically used Neu5Gc-presenting animal-derived
biotherapeutics (such as immunosuppressant rabbit anti-human
thymocyte globulin, ATG) elicited anti-Neu5Gc antibodies
(46, 47) with a profile that may be different from the “pre-
existing” ones (28, 48). The biological consequences of this have
not been revealed. A recent analysis showed that treating kidney
transplant patients with ATG did not increase the risk of colon
cancer (49). Neu5Gc has also been found on biodevices (such
as bioprosthetic heart valves) which may affect their duration
of function due to interaction with anti-Neu5Gc antibodies
which can lead to calcification (50, 51). Furthermore, Neu5Gc
in addition to α-Gal epitopes presented on animal tissues
causes barriers for animal-to-human xenotransplantation
(such as porcine skin xenografting and organ
xenotransplantation) (52, 53).
Neu5Gc and its glycosides are important tools for profiling
anti-Neu5Gc antibodies and sialic acid-binding proteins,
understanding Neu5Gc-related immune responses, and
designing potential therapeutics. To better understand
their important roles, it is critical to obtain structurally
defined glycans and glycoconjugates containing Neu5Gc or
its derivatives.
Neu5Gc and derivatives have been found and can be isolated
from natural sources including non-human mammals, some
higher invertebrates, such as sea urchin, sea cucumber, and
starfish (11, 23, 54, 55), as well as the surface of salmonid
fish eggs (56). For example, Neu5Gc has been extracted from
sea cucumber Cucumaria echinate in 99% purity. It constitutes
about 85% of the total sialic acids in dry weight of Gumi
(sea cucumber), and 23.6mg was obtained from 135 g of fresh
body weight (57). Neu5Gc-containing oligosaccharides have
been reported in the milk of primates, domestic herbivores, pigs,
lion, and leopard (58). So far, twenty-two Neu5Gc derivatives
(Figure 2) have been reported (1, 3). These include mono-, di-,
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FIGURE 1 | (A) Three basic forms of sialic acids including N-acetylneuraminic acid (Neu5Ac), N-glycolylneuraminic acid (Neu5Gc), and
3-deoxy-D-glycero-D-galacto-2-nonulosonic acid (Kdn); (B) Biosynthesis of Neu5Gc and its sialosides in eukaryotic cells. Enzymes and abbreviations: GNE,
UDP-GlcNAc 2-epimerase/ManNAc-6-kinase; NANS, Neu5Ac-9-P synthetase; NANP, Neu5Ac-9-P phosphatase; CSS, CMP-sialic acid synthetase; CMAH, cytidine
5′-monophosphate-N-acetylneuraminic acid hydroxylase.
and tri-O-acetylation at C4, C5, C7, C8, and/or C9 positions in
Neu5Gc as well as other modifications including O-methylation
at C5- or C8-, O-lactylation at C9, or O-sulfation at C8 or C9
of Neu5Gc with or without O-acetylation. Neu5Gc1,7lactone has
also been identified.
Neu5Gc and derivatives can link to other carbohydrate
moieties with different sialyl linkages including α2–3- and α2–
6-linked to galactose; α2–6-linked to N-acetylgalactosamine, N-
acetylglucosamine, galactose or glucose; α2–8- and α2–9-linked
to another Sia molecule; and α2–5-linked between polymers of
Neu5Gc (7, 10, 59–61), adding diversity to sialic acid-containing
compounds. The modification and linkage patterns of Sia play
a pivotal role in many biochemical processes, such as cell
signaling, cell-cell interaction, cellular adhesion, inflammation,
fertilization, viral infection and malignancies, and regulation of
apoptosis and proliferation (62, 63).
Numerous outstanding reports have been published
describing the synthesis of sialic acids and sialoside. The
focus, however, has been on Neu5Ac-containing compounds.
The synthesis of Neu5Gc-containing glycans is attracting an
increasing attention in recent years. This review provides an
overview of various chemical and chemoenzymatic synthetic
methods developed for the production of Neu5Gc and derivatives
as well as the corresponding sialosides.
CHEMICAL AND CHEMOENZYMATIC
SYNTHESIS OF Neu5Gc AND DERIVATIVES
Only a limited number of naturally occurring and non-
natural Neu5Gc derivatives have been chemically or
chemoenzymatically synthesized.
Neu5Gc was chemically synthesized from D-arabinose by
the Wong group. The C5-acylamino group of Neu5Gc and
a vinyl group were simultaneously introduced to D-arabinose
by a modified Petasis coupling reaction. The vinyl group
was then converted to γ-hydroxy-α-keto acid by a 1,3-dipolar
cycloaddition reaction with N-tert-butyl nitrone followed by a
base-catalyzed β elimination and hydrolysis to produce Neu5Gc
in 22% overall yield (64).
O-Acetylation is the most frequent modification of Neu5Gc
in nature. 9-O-Acetyl-Neu5Gc (Neu5Gc9Ac) has been found
in bovine submandibular gland glycoprotein (65, 66). On
the other hand, 4-O-acetyl-Neu5Gc (Neu4Ac5Gc) has been
found in horse glycoproteins (61), α2–8-linked polysialic
acids on glycoproteins from unfertilized kokanee salmon
egg (67), the serum of guinea pigs (68), and gangliosides
in human colon cancer tissues (69). Both Neu5Gc9Ac and
Neu4Ac5Gc have been successfully synthesized. The use of
orthoester intermediates is a very efficient method for producing
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FIGURE 2 | Naturally occurring Neu5Gc derivatives that have been identified.
various 9-O-acyl derivatives of Neu5Gc. Highly regioselective
acylation at C9-hydroxyl of Neu5Gc was achieved by the
treatment of Neu5Gc with a trimethyl orthoacetate in the
presence of a catalytic amount of p-toluenesulfonic acid (p-
TsOH) to form Neu5Gc9Ac in 90% yield. A similar strategy
was applied for the synthesis of non-natural derivatives of
Neu5Gc including 9-O-butyroyl-Neu5Gc and 9-O-benzoyl-
Neu5Gc in 88 and 70% yields, respectively (70). On the
other hand, Neu4Ac5Gc was synthesized using an efficient
chemoenzymatic approach involving a sialic acid aldolase-
catalyzed reaction from D-mannosamine (ManNH2) acylated
with a benzyl protected N-glycolyl group. The obtained N-(2-
benzyloxyacetyl)-D-mannosamine was enzymatically converted
to a Neu5Gc derivative in a quantitative yield by recombinant
Pasteurella multocida sialic acid aldolase (PmNanA) (71).
Following a number of selective protection strategies, 4-hydroxyl
group was selectively acetylated. The desired 4-OAc-Neu5Gc was
obtained in an overall yield of 46% after de-protection of other
hydroxyl groups (72).
In nature, the major function of sialic acid aldolases is to break
down sialic acids, such as Neu5Ac to form 6-carbon amino sugar
N-acetylmannosamine (ManNAc) and a three-carbonmetabolite
pyruvic acid. Nevertheless, they are capable of catalyzing the
reversed reaction and have been used as synthetically useful
enzymes for the formation of sialic acids and derivatives.
Sialic acid aldolase-catalyzed reactions can be a general and
highly efficient approach for chemoenzymatic synthesis of a
diverse array of Neu5Gc and derivatives from the corresponding
N-glycolylmannosamine (ManNGc) and derivatives. PmNanA
was found to have a better expression level and more
promiscuous substrate specificity than the more commonly used
Escherichia coli sialic acid aldolase (EcNanA) in catalyzing the
formation of sialic acids and derivatives (71). Both enzymes
have been used for chemoenzymatic synthesis of Neu5Gc and
derivatives. For the synthesis of Neu5Gc from ManNGc by sialic
acid aldolase-catalyzed reaction, ManNGc could be obtained
by chemical synthesis from D-mannosamine (ManNH2) (73,
74) or D-glucose (75), or by alkaline epimerization of
N-acetylglucosamine (GlcNAc) (76). For the synthesis of
ManNGc from ManNH2, the N-glycol group could be installed
using commercially available inexpensive acetoxyacetyl chloride
followed by de-O-acetylation by hydrolysis under a basic
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condition. However, it was found that ManNGc could be
epimerized to form N-glycolylglucosamine (GlcNGc) under
even mild basic conditions. Aspergillus niger lipase (Amano
A) was found to be efficient in de-O-acetylation without
the problem of epimerization (76). Installing the N-glycol
group usingN-succinimidyl glycolate (74) or 2-(benzyloxy)acetyl
chloride followed by hydrogenation (77) could also avoid
the complication of epimerization. The Neu5Gc formed went
through additional chemical reactions for the synthesis of
N-glycolyl-2,3-dehydro-2-deoxyneuraminic acid (Neu5Gc2en)
(78), a transition state analog inhibitor of some sialidases.
Together with N-acetyl-2,3-dehydro-2-deoxyneuraminic acid
(Neu5Ac2en), they have been found to be effective in protecting
mice from bacteria sepsis in a CD24/SiglecG-dependent manner
(79) in a cecal ligation and puncture (CLP) mouse model
(80). The protection was improved by combining the use of
Neu5Ac2en and Neu5Gc2en with antibiotic treatment (79). In
addition, Neu5Gc2en alone was effective in protecting mice from
endotoxemia by inhibiting mouse sialidase NEU1 expressed on
cell surface upon lipopolysaccharide (LPS) stimulation (81).
The sialic acid aldolase-catalyzed reactions can also be used
to synthesize naturally occurring and non-natural derivatives
of Neu5Gc. As shown in Figure 3A, Neu5Gc derivatives with
C5 and/or C9-modifications have been synthesized by sialic
acid aldolase-catalyzed reactions from C2- and/or C6-substituted
ManNGc derivatives as their 6-carbon sugar precursors (74,
82–87). Naturally occurring 8-O-methyl Neu5Gc (Neu5Gc8Me)
(Figure 3B) was also synthesized from chemically synthesized
5-O-methyl ManNGc (ManNGc5Me) by a PmNanA-catalyzed
reaction. A good yield of 86% was achieved using five
equivalents of sodium pyruvate in Tris-HCl buffer (100mM,
pH 7.5) at 37◦C for 24 h followed by the combination of
anion exchange chromatography and gel filtration column
purification (88).
EcNanA-catalyzed aldol addition of ManNGc and 3-fluoro-
pyruvate resulted in a mixture of 3F(equatorial)Neu5Gc and
3F(axial)Neu5Gc with a ratio of close to 1:1. They were readily
separated by a simple flash chromatography (Figure 3C) (89).
Disaccharides with a ManNGc at the reducing end could also
be suitable substrates for EcNanA. Two chemically synthesized
disaccharides Galα1–2ManNGc and Galβ1–2ManNGc were
used as the substrates for EcNanA for the synthesis of
the corresponding disaccharides Galα1–5Neu5Gc and Galβ1–
5Neu5Gc in 36 and 34% yields, respectively (Figure 3D) (85).
SYNTHESIS OF SIMPLE GLYCOSIDES OF
Neu5Gc
Simple glycosides of Neu5Gc have been synthesized from the
corresponding Neu5Ac derivatives by directly de-N-acetylating
the N-acetyl group of Neu5Ac under a strong basic condition
followed by acylation and deprotection. For example, as shown in
Figure 4A, the N-acetyl group in the carboxyl protected allyl α-
Neu5Ac-glycoside was removed to produce the free amino group
in 80% yield by refluxing in tetramethylammonium hydroxide.
Acylation with acetoxyacetyl chloride followed by hydrolysis of
the ester produced the desired allyl α-Neu5Gc-glycoside (90).
An improved microwave-assisted de-N-acetylation process was
also reported (91). In this case, fully protected methyl α-Neu5Ac
glycoside was treated with 2.0M of NaOH under an optimized
microwave irradiation condition (15min at 120◦C at a maximum
power of 100W) produced the desired 5-amino derivative in 91%
yield. The resulting compound was then converted to the target
methyl α-Neu5Gc glycoside (Neu5GcαOMe) by reacting with
acetoxyacetyl chloride, followed by de-O-acetylation (Figure 4B).
The same method was applied successfully for the formation of
Neu5Gc2en from per-acetylated Neu5Ac2en methyl carboxylate
as well as the production of poly-Neu5Gc from the corresponding
α2–8-linked homopolymer of Neu5Ac (91).
An 9-azido derivative of Neu5Gc2en (Neu5Gc9N32en) was
also chemically synthesized from Neu5Ac9N32en by substituting
the 9-hydroxyl group with an azido group followed by replacing
the -NHAc moiety with N-glycolyl group (92).
An alternative strategy for the synthesis of Neu5GcαOMe
(Figure 4C) involved enzymatic formation of Neu5Gc from
ManNGc using an EcNanA-catalyzed reaction. Protection of
Neu5Gc, followed by activation, glycosylation, and deprotection
led to the formation of the desired Neu5GcαOMe which was
used for ELISA inhibition assays and for purifying anti-Neu5Gc
antibodies from human sera (33).
CHEMICAL SYNTHESIS OF
Neu5Gc-CONTAINING
OLIGOSACCHARIDES
Several chemical glycosylation methods have been developed
for the synthesis of Neu5Gc-containing oligosaccharides. The
following discussion will be focused on different types of glycosyl
donors used.
Glycosyl Chloride Donors
A glycosyl chloride donor was used for synthesizing Neu5Acα2–
5Neu5Gc disaccharide which contained a sialyl α2–5-Neu5Gc
linkage similar to that found in the poly(-5Neu5Gcα2-) structure
on the jelly coat of sea urchin eggs (93). The strategy involved
the formation of an allyl glycoside of protected Neu5Ac as an
important intermediate which went through oxidative cleavage
of the C=C double bond in the allyl group (94) to form a
protected Neu5Ac glycoside with a carboxymethoxy aglycone.
Most recently, a similar strategy using protected Neu5Gc allyl
glycoside donor was applied in the synthesis of Neu5Gcα2–
5Neu5Gc disaccharide building block for the formation of
a tetrasaccharide capped with 9-O-sulfo-Neu5Gc (Neu5Gc9S)
found on sea urchin egg surface proteins (95).
The same Neu5Ac glycosyl chloride donor was used for
glycosylation with methyl glycolate. The glycosylated product
was deprotected and de-N-acetylated to form an amino-
containing intermediate which can be either protected by
a fluorenylmethyloxycarbony (Fmoc) group at the amino
group or by a methyl group on the carboxyl groups. The
resulting compounds were coupled to form the amide bond,
linking two sialic acid units together to produce the desired
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FIGURE 3 | (A) A general chemoenzymatic synthetic strategy of sialic acid aldolase (EcNanA or PmNanA)-catalyzed synthesis of Neu5Gc and derivatives containing
modifications at C5, C7, and/or C9 from ManNGc and derivatives, (B) PmNanA-catalyzed synthesis of Neu5Gc8Me, (C) EcNanA-catalyzed synthesis of
3-fluoro-Neu5Gc, and (D) EcNanA-catalyzed synthesis of disaccharides containing Neu5Gc at the reducing end.
disaccharide containing a Neu5Gc residue (96). α2–5-Linked
Neu5Gc oligomers for up to octasaccharide were also synthesized
using a similar strategy by coupling carboxyl and amine
protecting groups of sialic acid building blocks by amide
formation (97).
An O-acetyl protected Neu5Gc glycosyl chloride donor
was also used for the synthesis of Neu5Gcα2–3Galβ1–4Glc
trisaccharide building block for the formation of Neu5Gc-
GM3 ganglioside although with a low yield and a poor stereo-
selectivity (98).
Thioglycoside Donors
Sialyl thioglycoside donors have been widely applied in
chemically formation of sialyl glycosidic bonds. A thioglycoside
donor of Neu5Ac was used for the synthesis of Neu5Acα2–
5Neu5Gc disaccharide found as the structural component of the
jelly coat of sea urchin eggs. The strategy relied on the formation
of a protectedNeu5Ac glycoside with a carboxymethoxy aglycone
which was readily coupled with the amino group of the
protected neuraminic acid to form the desired amide bond in the
disaccharide (93).
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FIGURE 4 | Synthesis of Neu5Gc-glycosides by de-N-acetylation of Neu5Ac-glycoside derivatives without (A) or with (B) a microwave-assisted process and (C) by
glycosylation of protected Neu5Gc formed enzymatically from ManNGc and pyruvate.
Thioglycoside donors of Neu5Gc have also been used for
the synthesis of more complex Neu5Gc-containing sialosides.
The Kiso group reported the synthesis of protected Neu5Gcα2–
3GalβOMP disaccharide using N-2,2,2-trichloroethoxycarbonyl
(Troc)-protected thiophenyl sialoside donor which was
readily obtained from its corresponding N-acetyl derivative.
Sialylation of a selectively protected galactoside acceptor led
to the formation of sialyl disaccharide. Removal of the N-Troc
group by zinc in acetic acid formed a free amino group which
can be acylated with acetoxyacetyl chloride to produce the
desired protected Neu5Gc-containing disaccharide (99). A
similar strategy was used for the synthesis of a Neu5Gc8Me-
containing tetrasaccharide building block of the pentasaccharide
component, Neu5Gc8Meα2–3(Neu5Gc8Meα2–6)GalNAcβ1–
3Galβ1–4Glc, in GAA-7 ganglioside (100). In addition to the use
of acetoxyacetyl chloride as a reagent for introducing a protected
glycolyl group to the amino group on neuraminic acid (Neu)
residue for the formation of Neu5Gc, 1,3-dioxolan-2,4-dione
(101) prepared from glycolic acid was also used for the formation
of Neu5Gc-GM1 ganglioside directly from naturally more
abundant Neu5Ac version of GM1 (102).
The Sato group used a N-Troc-protected thiophenyl sialoside
donor for the synthesis of sialyllactoside component of
ganglioside LL3 tetrasaccharide. The removal of the N-Troc
group followed by conjugation with a protected Neu5Ac
glycoside with a carboxymethoxy aglycone and deprotection
steps formed the desired LL3 tetrasaccharide (103, 104).
The amino intermediate of the protected sialoside formed
after the removal of the N-Troc group could be converted
directly (99) to a 1,5-lactamized bicycle structure. Alternatively,
N-trifluoroacetyl (N-TFA)-protected thiophenyl sialoside donor
can also be used similarly for the formation of sialyl glycosides.
The N-TFA group could be readily removed and the resulting
amino group-containing intermediate could be converted to a
1,5-lactamized bicycle structure under mild basic conditions. The
resulting intermediate could be selectively protected at C-9 of
the sialic acid and used as a well-suited sialylation acceptor.
A similar N-Troc and 8,9-acetal-protected thiotoluene sialoside
donor was used for the synthesis of protected Neuα2–6GalαSer
as the sialyl Tn disaccharide building block that was coupled with
the pre-formed Neu5Gcα2–5Neu5Gc disaccharide component
for the formation of the sea urchin egg surface Neu5Gc9S-capped
tetrasaccharide (95).
Trisaccharide Neu5Gcα2–4Neu5Acα2–6Glc, a structural
component of ganglioside HLG-2, was synthesized by the
Kiso group by stereoselective coupling of N-Troc-protected
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thiophenyl Neu5Gc-sialoside donor with the pre-formed
Siaα2–6Glc 1,5-lactamized disaccharide acceptor (105, 106).
A similar strategy was used for the synthesis of Fucα1–
4Neu5Acα2–5Neu5Gcα2–4Neu5Acα2–6Glc, a pentasaccharide
component of HPG-7 ganglioside (107) and Fucα1–8Neu5Gcα2–
4Neu5Acα2–6Glc, a tetrasaccharide components of ganglioside
HPG-1 (108).
The Crich group reported the synthesis of Neu5Gc-containing
oligosaccharides in high stereoselectivity by iterative one-
pot route. A series of four trisaccharides were synthesized
in one pot by coupling of a 5N-acetoxyacetimide-5N, 4O-
oxazolidinone-protected adamantanyl thiosialoside donor with
the first thiogalactosyl acceptor followed by addition of the
second acceptor after 20 min (109).
The Nifant’ev group used an N-tert-butyloxycarbonyl (N-
Boc) and N-acetyl (N-Ac) protected thiophenyl sialoside donor
for the synthesis of 3-aminopropyl glycoside of Neu5Gcα2–
6LacNAc from N-acetyllactosamine (LacNAc) 4′,6′-diol acceptor
(30). A glycosylation yield of 84% with 1.3:1 (α:β) selectivity
was achieved. Removal of the N-acetyl and N-Boc groups
followed by N-acylation and subsequent deprotection steps
formed the desired trisaccharide. A similar strategy was used for
the synthesis of 3-aminopropyl glycoside of Neu5Gcα2–3LacNAc
using LacNAc 2′,3′,4′-triol acceptor (110).
Instead of installing N-glycolyl group after the formation of
sialyl glycosidic bond, properly protected Neu5Gc thioglycoside
donors could be directly used for glycosylation. For example,
an acetyl-protected thiophenyl Neu5Gc-glycoside donor was
used directly with α-selectivity and good sialylation yields
for the synthesis of Neu5Gc-containing glycosides including
sialyl Lewis × pentasaccharyl ganglioside analog (111) and
α2–3-sialyl lactotetraose and neolactotetraose derivatives (112).
A thiophenyl Neu5Gc-glycoside donor was also successfully
used for the synthesis of Neu5Gcα2–6GalOMP disaccharide
and its derivative Neu5Gc9N3α2–6GalOMP containing a
9-azido-9-deoxy-Neu5Gc residue. The 9-azido group of the
latter was converted to an amino group and the resulting
compound was used to generate a library of 9-N-acylated
derivatives of Neu5Gc-sialosides. Some of the compounds
were low-micromolar inhibitors of CD22 (or Siglec-2), a
well-known B cell-specific sialic acid-binding immunoglobulin-
like lectin (113). The same strategy was used to synthesize a
similar class of sialosides with different aglycons as improved
CD22 inhibitors with up to nanomolar potency (114, 115).
In addition to protected thiophenyl Neu5Gc-glycoside
donors, a benzyl-protected thiomethyl Neu5Gc-glycoside
donor was developed and used for the synthesis of
Neu5Gc-containing trisaccharides with 55–63% yields with
α-selectivity (116) and a sea cucumber disaccharyl ganglioside
analog (117).
Phosphite Donors
Phosphite donors of Neu5Gc are considered to be more reactive
than thioglycoside donors. They were used for the synthesis of
Neu5Gc-glycosides in propionitrile at −78◦C in good yields and
α-selectivity (Figure 5) (118).
FIGURE 5 | Efficient synthesis of Neu5Gc-glycosides using phosphite donors in good yields and α-selectivity.
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Trichloroacetimidate Donors
Trichloroacetimidate donors are the most commonly used
glycosyl donors. They have been used for the synthesis of
complex Neu5Gc-containing sialosides. The Kiso group reported
the first total synthesis of Neu5Gc8Me-containing ganglioside
GAA-7 which showed neuritogenic activity. The strategy
involved the assembly of the ceramide moiety by Witting,
Grignard, and amide formation reactions. Stereoselective
β-glycosylation with a glucosyl trichloroacetimidate donor
produced a glucosyl ceramide (GlcβCer) cassette which
was readily coupled with the protected Neu5Gc-containing
tetrasaccharyl trichloroacetimidate donor to form the
protected ganglioside. Global deprotection produced
GAA-7, a pentasaccharyl β-ceramide Neu5Gc8Meα2–
3(Neu5Gc8Meα2–6)GalNAcβ1–3Galβ1–4GlcβCer (119).
Protected Neu5Gc-containing disaccharyl trichloroacetimidate
donors have also been used for the synthesis of Neu5Gc-
containing glycans of lacto- and neolacto-series gangliosides.
The reducing ends of these oligosaccharides were further
modified by 2-(tetradecyl)hexadecanol to form glycolipid
mimics of ceramide-containing gangliosides (120).
N-Phenyltrifluoroacetimidate Donors
N-Phenyltrifluoroacetimidate (121) sialyl donors were designed
to improve their reactivity for glycosylation. The feature was
combined with 5-N-phthaloyl group protection of the sialyl
donors to favor α-sialyl isomer formation (122, 123) and allow
their suitability for one-pot procedures (124). As shown in
Figure 6, desired α-sialoside was stereoselectively synthesized
using this donor. The synthesized α-sialoside was further coupled
to another acceptor in one-pot to synthesize trisaccharides with
various internal disaccharide units. The 5-N-phthaloyl group on
sialic acid of trisaccharides was readily removed, acylated, and
deprotected to form the N-glycolyl group in Neu5Gc (124).
CHEMOENZYMATIC SYNTHESIS OF
Neu5Gc-CONTAINING
OLIGOSACCHARIDES
Sialyltransferase-catalyzed glycosylation can be considered
as the most efficient approach for the production of sialic
acid-containing structures. The strategy offers great advantages,
including high regioselectivity and stereoselectivity for the
formation of sialyl linkages as well as mild reaction condition
in aqueous solutions, etc. (2, 10). The increasing availability
of substrate promiscuous sialyltransferases in large amounts
makes the strategy practical even for large-scale synthesis. As
the sugar nucleotide donor, CMP-Neu5Gc, for sialyltransferase-
catalyzed synthesis of Neu5Gc-glycosides is not commercially
available, additional enzymes including CMP-sialic acid
synthetases (CSSs) with or without sialic acid aldolases are
commonly used. Although biosynthetically CMP-Neu5Gc is
directly synthesized from CMP-Neu5Ac by CMAH-catalyzed
hydroxylation, Neu5Gc is a well-tolerated substrate for
CSSs from bacterial sources including those from Neisseria
meningitidis (NmCSS), Escherichia coli (EcCSS), Streptococcus
agalactiae serotype V (SaVCSS), Pasteurella multocida strain P-
1059 (PmCSS), Haemophillus ducreyi (HdCSS), and Clostridium
thermocellum (CtCSS) (74, 125, 126). Among these, NmCSS with
a high expression level, a high specific activity, and substrate
promiscuity is an excellent choice for chemoenzymatic synthesis
of sialosides with or without sialic acid modifications (125).
Starting from pyruvate and a mixture of ManNGc and
GlcNGc, chemoenzymatic synthesis of trisaccharide Neu5Gcα2–
3Galβ1–3GalNAc, which has been found in porcine submaxillary
mucin, was achieved (127). As shown in Figure 7, Neu5Gc
was synthesized in 59% yield using an immobilized sialic acid
aldolase. It was used for the formation of CMP-Neu5Gc using
an immobilized calf brain CMP-sialic acid synthetase in 60%
yield. Sialylation of Galβ1–3GalNAcβOBn was carried out by
a porcine liver α2–3-sialyltransferase-catalyzed reaction using
CMP-Neu5Gc as donor. Deprotection by catalytic hydrogenation
produced the target trisaccharide Neu5Gcα2–3Galβ1–3GalNAc
in 56% yield.
As reaction conditions for sialic acid aldolase, CSS, and
sialyltransferase are compatible, they can be mixed together in
one-pot with ManNGc, pyruvate, CTP, and a sialyltransferase
acceptor for the synthesis of target Neu5Gc-glycosides. Such one-
pot multienzyme (OPME) sialylation reactions (82, 84, 86, 128)
are highly efficient for chemoenzymatic synthesis of a large
library of Neu5Gc-glycosides containing different sialyl linkages
and various internal glycans. Sialosides containing modified
Neu5Gc forms can also be produced by this strategy.
As shown in Figure 8A, in the OPME reaction containing
a sialic acid aldolase, a CSS, and a sialyltransferase, chemically
synthesized ManNGc or derivative is enzymatically converted to
Neu5Gc or derivative by the sialic acid aldolase. Activation of
the formed Neu5Gc or derivative to CMP-Neu5Gc or derivative
by CSS followed by sialylation led to the production of the
desired sialoside containing Neu5Gc or derivative. Both sialic
acid and CMP-sialic acid are generated in situ and do not need
to be purified.
If Neu5Gc and derivatives are available, OPME reaction
containing a CSS and a sialyltransferase without the presence
of a sialic acid aldolase (Figure 8B) is sufficient to produce
sialosides containing Neu5Gc or derivatives. The strategy is
particularly suited for sialosides containing a Neu5Gc derivative
that cannot be directly obtained by a sialic acid aldolase-catalyzed
reaction, such as Neu4Ac5Gc (72). The method was also used
for synthesizing sialosides containing 3F(equatorial)-Neu5Gc
or 3F(axial)-Neu5Gc. In this case, 3F(equatorial)-Neu5Gc, and
3F(axial)-Neu5Gc were pre-synthesized from ManNGc and
3-fluoro-pyruvate by EcNanA-catalyzed reaction and purified
before being subjected to OPME sialylation reactions.
Using efficient OPME sialyltransferase systems with two-
or three-enzymes (Figure 8), a diverse array of sialosides
including glycosphingolipid glycans, sialylated types 1–5
glycans, and sialyl Tn, containing Neu5Gc (Table 1) as
well as sialosides containing different Neu5Gc derivatives
including 3F-Neu5Gc, Neu4Ac5Gc, Neu5Gc9Ac, Neu5GcMe, or
Neu5GcAc (Table 2) have been synthesized. The obtained
compounds have been used to construct sialyl glycan
microarrays (28, 33, 34, 42, 83, 150–156), sialoside-protein
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FIGURE 6 | An example of one-pot chemical synthesis of Neu5Gc-containing trisaccharides using 5-N-phthaloyl group protected N-phenyltrifluoroacetimidate sialyl
donor.
FIGURE 7 | Chemoenzymatic synthesis of Neu5Gcα2–3Galβ1–3GalNAc.
FIGURE 8 | Synthesis of sialosides containing Neu5Gc or derivative using one-pot multienzyme (OPME) sialylation systems containing (A) three enzymes including
sialic acid aldolase (NanA), CMP-sialic acid synthetase (CSS), and sialyltransferase (SiaT) or (B) two enzymes including CSS and SiaT.
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TABLE 1 | Chemoenzymatically synthesized Neu5Gc-containing glycans.
Neu5Gc-glycosides References Neu5Gc-glycosides References Neu5Gc-glycosides References
Ganglio-series
GM3 type glycans
(77, 127) (129) (130)
(29, 84) (84)
GM2 type glycans
(51)
GM1 type glycans
(77)
GD3 type glycans
(77) (29, 86) (29, 86)
(29, 86) (77) (77)
(131) (29, 86) (86)
(77) (77) (29, 86)
GD2 type glycans
(77) (77) (77)
(77) (77)
GD1b type glycans
(77) (77) (77)
(Continued)
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TABLE 1 | Continued
Neu5Gc-glycosides References Neu5Gc-glycosides References Neu5Gc-glycosides References
Lacto-series
(77) (83) (29, 132, 133)
(83) (134)
Neolacto-series
(77) (83) (77)
(83)
Globo- and isoglobo-series
(77) (77)
Sialylated types 1–5 glycans
(29) (29, 132) (130, 135)
(130, 135) (29, 132) (29, 132)
(127) (29, 132) (29, 132, 136)
(83) (29) (137)
(29) (130, 135) (29, 82)
(Continued)
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TABLE 1 | Continued
Neu5Gc-glycosides References Neu5Gc-glycosides References Neu5Gc-glycosides References
(130, 135) (83) (138)
(29)
Sialyl Tn
(29, 87) (130, 135, 139)
Sialyl Lea
(140)
Sialyl Lex
(29, 141) (29, 142) (142)
(142)
Sialyl Lactuloses
(143) (143)
Mammalian O-Mannose glycans
(144) (145) (145)
(145) (145) (145)
(145) (145) (145)
(Continued)
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TABLE 1 | Continued
Neu5Gc-glycosides References Neu5Gc-glycosides References Neu5Gc-glycosides References
(145) (145) (145)
(145) (145) (145)
(145) (145) (145)
(145) (145) (145)
(145) (145) (145)
(145) (145) (145)
(145) (145)
Sialylated Poly-Lacnac
(146) (146) (146)
(Continued)
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TABLE 1 | Continued
Neu5Gc-glycosides References Neu5Gc-glycosides References Neu5Gc-glycosides References
(146)
N-Glycans
(83) (83) (147)
(147) (147) (147)
(147) (147) (147)
(147) (147) (147)
(146, 147)
Glc, Gal, Neu5Ac, Neu5Gc, Kdn, GalNAc, Fuc, GlcNAc, Man, Fruc. All, allyl group; Me, methyl; ProN3, propyl azide; ProNH2, propyl amine; Glucityl-AEAB,
the reductive amination product of glucose and 2-amino-N-(2-aminoethyl)-benzamide.
conjugates (148), and sialidase substrate specificity studies
(131, 157–159). Among bacterial sialyltransferases used,
Pasteurella multocida sialyltransferase 1 (PmST1) (84)
and its single mutant PmST1 M144D with decreased
donor hydrolysis and sialidase activities (141) were broadly
applied for the synthesis α2–3-linked sialyl oligosaccharides
containing Neu5Gc, 3F-Neu5Gc, Neu5Gc9Ac, Neu5GcMe,
or Neu5GcAc (77, 83, 84, 89, 157, 160). For synthesizing α2–
3-sialyl oligosaccharides containing Neu4Ac5Gc, however,
only Pasteurella multocida sialyltransferase 3 (PmST3)
(161) was found to be a suitable enzyme (72). PmST3 was
also well-suited for the synthesis of α2–3-linked Neu5Gc-
containing sialyl glycopeptides (162). Photobacterium damselae
α2–6-sialyltransferase (Pd2,6ST) (82), Photobacterium species
α2–6-sialyltransferase (Psp2,6ST) (87) and its single mutant
with improved expression level and slightly enhanced activity
Psp2,6ST A366G (163) were used for synthesizing α2–6-
linked sialosides containing Neu5Gc, 3F-Neu5Gc, Neu5Gc9Ac,
Neu5GcMe, or Neu5GcAc (82, 83, 89, 157, 160). Psp2,6ST
was well-suited for the synthesis of sialyl Tn-antigens (Sia
α2–6GalNAcαOR) (87). Campylobacter jejuni sialyltransferase
CstII (CjCstII) (164) was found to be an efficient sialyltransferase
for the synthesis of a diverse array of Neu5Gc-containing
α2–8-linked sialosides (77, 86, 131). For synthesizing sialosides
containing Neu5Gc or its stable analogs, such as 3F-Neu5Gc and
Neu5GcMe, the pH of the OPME reactions was controlled at
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TABLE 2 | Chemoenzymatically synthesized sialosides containing 3FNeu5Gc, Neu4Ac5Gc, Neu5Gc9Ac, Neu5GcMe, Neu5GcAc, or Neu5GcBn.
Sialosides References Sialosides References Sialosides References
3FNeu5Gc-containing glycans
(63) (63) (63)
Neu4Ac5Gc-containing glycans
(72) (72) (72)
(72) (72) (72)
(72)
Neu5Gc9Ac-containing glycans
(128) (128) (128)
(128) (128) (128)
(29, 82, 148) (29, 148) (149)
(149) (86) (83)
(83) (83) (83)
(140) (141)
(Continued)
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TABLE 2 | Continued
Sialosides References Sialosides References Sialosides References
Neu5GcMe-containing glycans
(87) (29, 86) (83)
(83) (83) (83)
(83) (83)
Neu5GcAc-containing glycans
(87) (83) (83)
(83) (83) (83)
Neu5GcBn-containing glycans
(87)
Glc, Gal, Neu5Ac, Neu5Gc, Fuc, GalNAc, Man, GlcNAc. Me, methyl; ProN3, propyl azide; ProNH2, propyl amine; Glucityl-AEAB, the reductive amination product
of glucose and 2-amino-N-(2-aminoethyl)-benzamide.
8.5 to allow highly efficient catalysis by all enzymes involved in
the reactions. For synthesizing sialosides containing base-labile
groups, such as Neu4Ac5Gc, Neu5GcAc, or Neu5Gc9Ac, the
pH of the OPME reactions was controlled at 7.0 to minimize
de-O-acetylation during the reaction.
Recently, the OPME α2–3-sialylation system containing
PmNanA, NmCSS, and PmST1 M144D was coupled with
Streptococcus pneumoniae sialidase SpNanC-catalyzed reaction
for the formation of Neu5Gc2en from ManNGc, pyruvate, CTP,
and lactose (165).
CHEMOENZYMATIC SYNTHESIS OF
Neu5Gc-CONTAINING
GLYCOCONJUGATES
The alkyl azido aglycone in chemoenzymatically synthesized
Neu5Gc-containing sialosides can be readily converted to
an alkyl amino group by catalytic hydrogenation to allow
convenient conjugation with N-hydroxysuccinimide-activated
or epoxide-activated slide surface for generating glycan
microarrays (34). It was also used to react with adipic acid
p-nitrophenyl diester to form half-esters which were coupled
to the amino group (e.g., in lysine residues) of biotinylated
human (STn) antigens Neu5Gc/Neu5Gc9Acα2–6GalNAcαOR
(Figure 9A) and sialyl lactosides Neu5Gcα2–6Galβ1–
4GlcβOR (Figure 9B) containing Neu5Gc or Neu5Gc9Ac
were successfully synthesized and used for ELISA inhibition
studies (33, 148).
OPME chemoenzymatic sialylation reactions have also been
used in the synthesis of sialyl-Tn-MUC1 and sialyl-T-MUC1
glycopeptides containing Neu5Gc (Figure 9C). Pasteurella
multocida α2–3-sialyltransferase (PmST3), Photobacterium
damselae α2–6-sialyltransferase (Pd2,6ST) Neisseria meningitidis
CMP-sialic acid synthetase (NmCSS) and E. coli sialic acid
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FIGURE 9 | Synthesis of biotinylated human serum albumin-sialoglycoside conjugates containing Neu5Gc or Neu5Gc9Ac including (A) sTn epitopes, (B) sialyl
lactoside, and (C) chemoenzymatic synthesis of dabsyl fluorophore-tagged glycopeptides including sTn, T, and ST-antigens containing Neu5Gc. Adopted and
modified from Yu et al. (148) and Malekan et al. (162) with permission.
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aldolase are the enzymes used for OPME sialylation of
glycoproteins (162).
Hidari et al. recently reported the synthesis of multivalent
Neu5Gc-containing sialoglycopolypeptides. Treating the
chemically synthesized Lac or LacNAc-carrying peptides
as acceptors and CMP-Neu5Gc as the donor substrate,
sialoglycopolypeptides with α2–3- and α2–6-sialyl linkages were
obtained in the presence of ST3Gal III or ST6Gal I, respectively.
They found that multivalent α2–3-linked Neu5Gc-ligands
selectively inhibited hemagglutination mediated by influenza
viruses with a strong inhibitory activity (166). Hernaiz et al.
also reported that the enzymatic approach could be directly
applied to sialylating lactose-carrying glycoclusters using α2–6-
sialyltransferase from rat liver and CMP-Neu5Gc as the donor to
produce Neu5Gc-containing glycoclusters (167).
CONCLUSIONS AND PERSPECTIVE
Significant advances have beenmade in the synthesis of sialosides
although the focus has been on those containing Neu5Ac, the
most common sialic acid form. With the increasing recognition
of the presence and the important functions of Neu5Gc and
human anti-Neu5Gc xeno-autoantibodies, more attention has
been and will be paid to the synthesis of sialosides containing
Neu5Gc and its derivatives. Chemical synthetic methods
developed for the formation of Neu5Ac-containing molecules
can be extended to Neu5Gc counterparts with modifications.
Chemoenzymatic methods using sialyltransferases have been
recognized as efficient strategies for accessing challenging sialic
acid-containing molecules including those containing Neu5Gc
and derivatives. Among these, one-pot multienzyme (OPME)
systems have been proven powerful tools. Large library of
sialosides containing Neu5Gc and derivatives will become
available for elucidating their biological roles and exploring
their potential applications. These will be indispensable probes
for profiling anti-Neu5Gc antibodies and investigating other
Neu5Gc-binding proteins. Such information will help us to
better understand the physiological and pathological roles of
Neu5Gc and its binding partners. Combining sialidase-treatment
and sialyltransferase-catalyzed re-sialylation with Neu5Gc or
Neu5Ac will be a potentially efficient approach for generating
glycoconjugates with a desired sialic acid form for improved
therapeutic applications.
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